Rapt Therapeutics (RAPT) Stock Price, News & Analysis

Company Overview

RAPT Therapeutics, Inc (NASDAQ:RAPT) is a clinical-stage biotechnology company developing novel therapeutics for autoimmune and allergic diseases. Founded in 2013 and headquartered in San Diego, California, RAPT applies tissue-selective immunology to design small molecule and biologic candidates that modulate immune cell trafficking and tissue-resident pathways. The company’s research platform enables the identification of targets that drive tissue inflammation with the goal of achieving improved efficacy and safety profiles over current therapies.

The company’s lead asset, RPT193, is an orally available antagonist of the CC chemokine receptor 4 (CCR4), currently in clinical development for atopic dermatitis and allergic asthma. By selectively blocking CCR4-mediated migration of pathogenic T cells to inflamed tissues, RPT193 aims to reduce disease activity without broad immunosuppression. RAPT is also advancing discovery-stage programs against additional chemokine receptors involved in tissue inflammation, including efforts in ulcerative colitis and other indications.

Since its initial public offering in 2020, RAPT has expanded its operations across the United States, leveraging partnerships and collaborations to extend its global reach. The company maintains research and development facilities in San Diego and engages with clinical sites worldwide to advance its pipeline.

Under the leadership of Chief Executive Officer John C. Huggins, RAPT’s management team brings extensive experience in immunology, drug discovery and clinical development. The organization is guided by a board of directors and scientific advisors with deep expertise in translational research and biopharmaceutical innovation.

Key Stats

• Today's Range: $58.02 to $58.02
• 50-Day Range: $57.61 to $58.02
• 52-Week Range: $5.67 to $58.02
• Volume: N/A
• Average Volume: 4.25 million shs
• Market Capitalization: $1.61 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $59.83
• Consensus Rating: Hold

Company Calendar

• Last Earnings: 11/06/2025
• Today: 10/12/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:RAPT
• CIK: 1673772
• Web: www.rapt.com
• Phone: (650) 489-9000
• Fax: N/A
• Employees: 80
• Year Founded: 2015

Price Target and Rating

• Average Price Target for Rapt Therapeutics: $59.83
• High Price Target: $70.00
• Low Price Target: $57.00
• Potential Upside/Downside: +3.1%
• Consensus Rating: Hold
• Rating Score (0-4): 2.00
• Research Coverage: 10 Analysts

Profitability

• EPS (Trailing Twelve Months): ($11.06)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$129.87 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -61.81%
• Return on Assets: -54.73%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 12.04
• Quick Ratio: 12.04

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $11.51 per share
• Price / Book: 5.04

Miscellaneous

• Outstanding Shares: 27,711,000
• Free Float: 27,057,000
• Market Cap: $1.61 billion
• Optionable: Optionable
• Beta: 0.49